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Introduction
N-3 polyunsaturated fatty acids (PUFAs) has an advantageous impact on patients with stable ASCVD, what was supported by the first landmarks studies [1] [2] [3] [4] . It was demonstrated that serum concentrations of n-3 PUFAs were inversely associated with total mortality, independent of CV risk factors [4] . During the improvement of optimal CV therapy, the results of subsequent randomized controlled trials have challenged previous beneficial observational and interventional data [1] [2] [3] . It was shown that type 2 diabetes (T2D) could reduce this beneficial effect, at least in patients with established ASCVD [5] [6] [7] [8] . Since then, there have been conflicting results on the impact of n-3 PUFA on CV events [4, [9] [10] [11] . A systematic review of randomized controlled trials did not found any significant effects of n-3
PUFAs on the mortality or CV events [12] . However, a recently published REDUCE-IT study brought our attention on the proper dosage of eicosapentaenoic acid (EPA) ethyl ester in highrisk patients with established ASCVD or T2D, and demonstrated a significant reduction of CV mortality [13] [14] . Therefore, we sought to investigate the differences in FAs composition in serum phospholipids between the patients with established acute phase myocardial infarction (MI) and high-risk stable ASCVD, and their predictive value in diagnosis of MI.
Methods

Study population MI group
We assessed 83 patients hospitalized within 12 hours from the onset of the first clinical symptoms of MI. Both ST elevation MI (STEMI) and non-ST elevation MI (NSTEMI) patients were included in the study. Inclusion criteria included ST elevation MI (STEMI), non-ST elevation MI (NSTEMI) and age ≥ 45 years. Both STEMI and NSTEMI diagnoses were established according to the Third Universal Definition of Myocardial Infarction [15] [16] [17] [18] [19] . Exclusion criteria were as follows: prior n-3 PUFA treatment, known sensitivity or allergy to fish or PUFA supplements (or other situations resulting in a lack of dietary intake of n-3 or n-6 PUFAs), pregnancy, active bleeding, acute infection, serum creatinine levels >177 μmol/L (2 mg/dL), liver injury [alanine transaminase (ALT) levels >1.5 times above the upper limit of the reference range], alcohol or drug abuse, history of malignancy (unless disease free for >10 years or non-melanoma skin carcinoma), life expectancy <12 months due to concomitant diseases, abnormal findings on laboratory or imaging tests which would interfere with the interpretation of results, and any threatening condition during the study.
Control group
As a control group, we assessed 74 patients from the outpatient cardiology clinic with established stable ASCVD and T2D. The exclusion criteria were: acute coronary syndrome (within the previous 3 months), percutaneous coronary intervention or coronary artery bypass grafting (within the previous month), percutaneous or surgical revascularization (within the previous month). Other exclusion criteria were similar to the MI group. 
Results
Baseline characteristics
Final analysis included 52 subjects in the MI group and 74 subjects in the control group. Baseline characteristics of the study patients, including comorbidities and medications are shown in Table 1 . We did not observe any significant differences in age, gender, current smoking status, prior MI, hypertension, and chronic kidney disease between the 2 groups.
However, the percentage of patients with obesity, T2D and antidiabetic medication were significantly higher in patients with control group (Table 1 ). In addition, as expected there were significant differences between the two groups in high-sensitivity C-reactive protein (hsCRP) levels, lipid profile (Table 2) , left ventricular ejection fraction (LVEF), and some of the drugs used e.g.: clopidogrel or acetylsalicylic acid (Table 1) .
FA composition in serum phospholipids
In both groups, SFAs composed the largest fraction of serum phospholipid fatty acids Significant differences between the MI and control groups were found in every type of FA fraction of serum phospholipid, including: SFAs, MUFAs, n-3 PUFAs, n-6 PUFAs (Table   3) . Importantly, total SFAs, total MUFAs, total n-6 PUFA and n-6/n-3 ratio significantly differed between the studied groups ( Figure 1) . Interestingly, there were no significant differences in DHA and EPA concentrations between the MI group and control group.
Considering single FAs, palmitic acid formed the largest fraction of serum phospholipids in both groups with 31.9% and 31.16% in the MI and control group, respectively. In the MI group, LA and AA were the second and third largest fractions of serum phospholipids (16.4% and 15.8%, respectively). Meanwhile, in the control group, AA was the second largest fraction while LA comprised the third largest fraction (17.6% and 14.4%, respectively) ( Table 3) .
Univariate and multivariate logistic regression analyses
Statistically significant predictors of myocardial infarction in the study population are presented in Table 4 . Multivariate logistic regression analysis demonstrated that BMI, LDL-C, AST, hsCRP, POA (C16:1), and EDA (C20:2) were independent predictors of MI in our study population (Table 4 ). The predictive model showed a high degree of cross-validated calibration and discrimination with AUC =0.99.
Discussion
In our study we demonstrated that patients with MI had significantly increased concentrations of total n-6 PUFAs, total SFAs, total MUFAs, and increased n-6/n-3 ratio when compared to patients with stable ASCVD. Furthermore, to the best of our knowledge, this is the first study to show that the concentration of POA (MUFA) and EDA (n-6 PUFA) are independent predictors of myocardial infarction. We found that higher concentrations of both FAs, together with known CV risk factors such as LDL-C and hsCRP levels, were significantly associated with the MI.
It was previously shown that the FA composition of serum phospholipids is dependent on the dietary intake of FAs during the previous weeks. However, in addition to diet, the concentration of FA is determined by endogenous FA metabolism including FA synthesis, FA desaturation, elongation, retro-conversion, and oxidation [6, 20, 21] .
SFAs
Current European Society of Cardiology (ESC) Guidelines on CV disease Prevention
in Clinical Practice recommend to reduce the intake of SFAs to <10% of total energy, through replacement by PUFAs [22] . It was calculated that the risk of CAD is reduced by 2-3% when 1% of energy intake from SFAs is replaced by PUFAs [22, 23] . It was demonstrated that even isocaloric replacement of SFAs with PUFAs resulted in reduction of LDL-C and TC/HDL-C ratio, which are established risk factors for CAD [24] . A recent analysis of EPIC-Norfolk and EPIC-Denmark cohorts by Praagman et al. suggested that a higher consumption of C4:0-C10:0 and C12:0, C14:0 was associated with a lower MI risk [25] . The conflicting evidences of the association between SFAs and CAD could be due to differences in types of SFAs, based on their carbon-atom chain lengths [25] . In our study, majority of SFAs were inversely associated with MI, however lauric acid (C12:0) with the highest carbon-atom chain remained without a significant statistical difference between the studied groups.
MUFAs
Interventional studies demonstrated that MUFAs could improve CV risk factors, but prospective data with regard to CAD risk is limited and remain controversial [26] [27] [28] [29] . It was found that total intake of MUFAs have a significant inverse association with total mortality, nonetheless no association with CAD was observed [30] . Some authors underline the role of MUFAs origin in their impact on CV diseases [27] . Replacement of SFAs with plant-based MUFAs was associated with significantly lower risk of CAD when compared to animal-based MUFAs [27] . Some epidemiological evidence suggests that the length of carbon chains in MUFAs might play a role in prediction of CV diseases [31] . Zhongxia Li et al. demonstrated that higher long-chain (14-18 carbon atoms) MUFAs concentrations had a beneficial impact on all-cause and CV mortality, while very long-chain MUFAs (≥ 20 carbon atoms) contributed to the higher mortality [31] .
n-3 PUFAs
In our study only the ALA (C18:3) concentration was significantly higher in MI group. We did not observe any significant differences between other n-3 PUFAs, including DHA and EPA. A recent systematic review of n-3 PUFAs randomized control trials demonstrated no benefit of n-3 PUFAs on effects on mortality or CV events [12] . In VITAL study (treatment with 1 g of n-3 PUFAs daily) in the primary CV prevention, the authors found a significant 19% reduction of MACE, but only in subjects with low fish consumption [32] . On the contrary, the REDUCE-IT trial which investigated the impact of high-dose n-3 PUFA (4 g daily; pure EPA ethyl ester) on patients with established CV disease or with T2D and other CV risk factors, demonstrated significantly beneficial results of n-3 PUFAs intervention including reduction in MACE of 25% [13] . Finally, the membrane composition of FA (especially EPA and DHA) in the inflammatory cells could alter their function.
Therefore, the anti-inflammatory impact of those acids may contribute to their protective actions towards the withhold of the atherosclerosis process and the plaque rupture [33] .
n-6 PUFAs and n-6/n-3 ratio
A multicenter trial by Nishizaki et al. found that low EPA/AA, but not DHA/AA ratio, had a significant association with the occurrence of MI [34] . In our study, EPA/AA and DHA/AA ratios were similar in both groups. Nevertheless, we observed that the n-6/n-3 ratio and total n-6 PUFAs were much higher in the MI group when compared to the controls.
It was found that concentration of LA was inversely associated with the occurrence of MI [35] . It was demonstrated that low serum levels of n-6 could predict poor long-term prognosis in patients with acute CV disease. Namely, decreased dihomo-γ-linolenic acid (DGLA) levels were associated with increased total mortality in patients with acute CV disease. However, DGLA and AA have the opposite effects, mainly due to their metabolites.
The pro-inflammatory effect of AA comes from the conversion to series 2 prostaglandins and series 4 leukotrienes, which are attributed to induce platelet aggregation, inflammation and vasoconstriction [36, 37] . On the other hand, DGLA undergoes oxidative metabolism to beneficial, anti-inflammatory eicosanoids (PG of series 1 and LK of series 3) [36, [38] [39] [40] .
Palmitoleic and eicosadienoic acids
Although previous studies have discussed the impact of POA on the risk and progression of ASCVD [41] [42], but none of them analyzed the influence of POA in patients with MI. POA was found to act as a lipokine and could be considered as a metabolic modulator [43] . Furthermore, POA was associated with decreased LDL-C, fibrinogen and increased HDL-C [43] [44] [45] .
Based on the available literature, we were unable to find any studies regarding the association of EDA and acute phase of MI. EDA is a naturally occurring n-6 polyunsaturated FA and a relatively minor metabolite of LA. EDA can further be metabolized to i.a. AA, thereby giving it pro-inflammatory properties [46] . In our study, we demonstrate a novel association between EDA and ASCVD, specifically in patients with MI.
Limitations
First, the cross-sectional nature of the study did not allow us to infer causality and a follow-up was not performed. Second, our patients were provided with dietary advice regarding low-fat and low-carbohydrate meals, but dietary fat intake was not determined. Third, the higher presence of obesity and T2D in the control group could challenge the inference between the groups. Finally, in the multiple logistic regression model for MI per one unit increase in EDA showed opposite results vs. simple logistic regression model for EDA, what was confirmed also after eliminating the observations with the highest influence on the model (Cook's distance). This could be a case of Simpson's paradox resulting from adjustment for known risk factors such as LDL-C.
The major differences in the FA composition of serum phospholipids between the MI group and patients with high-risk ASCVD and T2D concerned the higher content of SFAs, MUFAs, n-6 PUFAs and the n-6/n-3 ratio. In a multivariate analysis, aside from known CV risk factors, EDA and POA were independent predictors of MI. Data presented as median and interquartile range. Abbreviations: hsTnT, high-sensitive troponin T; HbA1c, glycated hemoglobin; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AST, aspartate transaminase; ALT, alanine transaminase; hsCRP, highsensitive C-reactive protein, eGFR, estimated glomerular filtration rate (MDRD formula). A distribution of fatty acid composition in serum phospholipids in patients with myocardial infarction vs. control group. Abbreviations: FAs, fatty acids; SFAs, saturated FAs; MUFAs, monounsaturated FAs; n-3 PUFAs, n-3 polyunsaturated FAs; n-6/n-3 ratio, n-3 PUFAs to n-6 PUFA ratio; EPA/AA, eicosadienoic acid to arachidonic acid ratio; DHA/AA, docosahexaenoic acid to arachidonic acid ratio.
